Post-earnings recap
Reported
Wed, Mar 11, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. The stock's modest drop of 0.19% reflects a cautious sentiment in the market following the earnings announcement.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -62.71% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach in light of the recent performance. They emphasized their commitment to ongoing development efforts.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current challenges.